Liver Cirrhosis: Diagnosis and Treatment

1. Definition and Pathology

A: Normal liver (smooth surface). B: Normal sinusoidal architecture on microscopy. C: Cirrhotic liver (orange-tawny color, irregular nodular surface). D: Microscopy showing regenerative nodules surrounded by fibrous tissue.

Important note: Cirrhosis regression can occur with disease remission or cure. Scars thin, compact, fragment, and adjacent nodules coalesce. All cirrhotic livers contain elements of both progression and regression.

• Goldman-Cecil Medicine, p. 1614-1615
• Robbins & Kumar Basic Pathology, p. 598

2. Etiology

• Goldman-Cecil Medicine, Table 139-1, p. 1615

3. Staging

• Goldman-Cecil Medicine, p. 1615

4. Pathophysiology of Complications

A. Portal Hypertension + Hyperdynamic Circulatory State

• Fixed component: Deposition of fibrous tissue and compression by regenerative nodules
• Functional component: Active vasoconstriction due to intrahepatic nitric oxide (NO) deficiency
• Leads to splanchnic vasodilation, which maintains portal hypertension even as portosystemic collaterals develop
• Hepatic Venous Pressure Gradient (HVPG) >6 mmHg = portal hypertension; >10 mmHg = development of varices; >12 mmHg = risk of variceal bleeding

• Esophagogastric varices - develop in ~40% of advanced-stage patients; may cause fatal hematemesis
• Ascites - fluid transudate in peritoneal cavity (serum-to-ascites albumin gradient [SAAG] ≥1.1 g/dL); ~85% of all ascites is from portal hypertension due to cirrhosis
• Splenomegaly - leading to hypersplenism (thrombocytopenia, pancytopenia)
• Caput medusae - abdominal wall collateral vessels

B. Liver Insufficiency

• Jaundice - failure to excrete bilirubin
• Coagulopathy - reduced clotting factor synthesis
• Hypoalbuminemia - reduced albumin synthesis
• Hepatorenal Syndrome (HRS) - functional renal failure; vasodilators (nitric oxide) cause decreased renal perfusion, activating renin-angiotensin axis and renal sympathetic system
• Hyperestrogenemia (in men) - impaired estrogen metabolism leading to spider angiomas, palmar erythema, gynecomastia, testicular atrophy, hair loss

C. Hepatic Encephalopathy (both mechanisms)

• Neuropsychiatric manifestations; ~2-3% per year incidence
• Grades: 1 (sleep-wake inversion, forgetfulness) → 2 (confusion, disorientation) → 3 (lethargy, profound disorientation) → 4 (coma)
• Hallmark sign: asterixis (flapping tremor)
• Sweet-smelling breath = fetor hepaticus

D. Spontaneous Bacterial Peritonitis (SBP)

• Complication of ascites; infection without apparent surgical source

E. Pulmonary Complications

• Hepatopulmonary syndrome - exertional dyspnea, clubbing, cyanosis, vascular spiders; present in 5-10% awaiting transplant
• Portopulmonary hypertension - exertional dyspnea, syncope, chest pain
• Goldman-Cecil Medicine, p. 1616-1618
• Robbins & Kumar Basic Pathology, p. 598-600

5. Diagnosis

Clinical Presentation

• ~40% of cirrhotic patients are asymptomatic until advanced stages
• Early/nonspecific: anorexia, weight loss, weakness

Physical Examination Signs

Laboratory Tests

Imaging Studies

• Ultrasound: nodular liver contour, splenomegaly, ascites, collateral vessels
• CT scan: nodular contour, small liver (±caudate/left lobe hypertrophy), collaterals (portal hypertension sign)
• MRI: detailed characterization of liver architecture and vasculature
• Transient elastography (FibroScan)/Acoustic Radiation Force Impulse (ARFI): measures liver stiffness - excellent noninvasive tool for diagnosing and excluding cirrhosis (AASLD-endorsed, supported by 2025 systematic review [PMID: 38489521])
• MR elastography: highly accurate for staging fibrosis

Portal Pressure Measurement

• Hepatic venous pressure gradient (HVPG): via hepatic vein catheterization (wedged minus free pressure)
  • Normal: 3-5 mmHg
  • Portal hypertension: ≥6 mmHg
  • Clinically significant: ≥10 mmHg (varices develop)
  • Variceal bleeding risk: >12 mmHg
  • HVPG is normal in prehepatic causes (portal vein thrombosis) and in presinusoidal intrahepatic causes (schistosomiasis)

Liver Biopsy

• Gold standard for definitive diagnosis and determining degree of inflammation
• Invasive; subject to sampling error
• Not required when decompensated cirrhosis is evident (ascites + variceal bleeding + encephalopathy in context of chronic liver disease essentially establishes diagnosis)
• Indicated when: diagnosis uncertain, degree of inflammation unclear, or etiology undetermined
• Goldman-Cecil Medicine, p. 1617-1620

Prognostic Scoring Systems

• Child-Pugh score (bilirubin, albumin, PT/INR, ascites, encephalopathy): Class A (compensated), B, C (advanced)
• MELD score (creatinine, bilirubin, INR): used for liver transplant prioritization

6. Treatment

A. Etiology-Specific Treatment

B. General Management

• Nutrition: 25-35 kcal/kg/day and 1.2-1.5 g protein/kg/day (compensated); 30-35 kcal/kg/day and 2.0 g/kg/day protein (decompensated)
• Exercise: Aerobic (3 days/week) + resistance training (2 days/week) - improves muscle mass and cardiovascular fitness
• Avoid NSAIDs, nephrotoxins, hepatotoxic drugs
• Vaccinations: Hepatitis A, B, influenza, pneumococcal

C. Management of Complications

Portal Hypertension / Varices

• Non-selective beta-blockers (NSBBs) - propranolol or carvedilol: primary prevention of first variceal bleed (if HVPG >10 mmHg or varices present)
• Endoscopic variceal ligation (EVL): alternative to NSBBs or combined for secondary prophylaxis
• Acute variceal hemorrhage: IV terlipressin or octreotide + EVL + antibiotics (norfloxacin or ceftriaxone for 7 days)
• TIPS (Transjugular Intrahepatic Portosystemic Shunt): for refractory bleeding or recurrent hemorrhage

Ascites

• Sodium restriction (<2 g/day)
• Diuretics: spironolactone (first-line, 50-400 mg/day) ± furosemide (40-160 mg/day)
• Large-volume paracentesis (LVP): for tense/refractory ascites (replace with albumin 8 g/L of fluid removed)
• TIPS: for refractory ascites in selected patients

Spontaneous Bacterial Peritonitis (SBP)

• Diagnosis: Ascitic fluid PMN count ≥250 cells/mm³
• Treatment: IV cefotaxime (or ceftriaxone) + IV albumin (1.5 g/kg at diagnosis, 1.0 g/kg on day 3) to prevent HRS
• Prophylaxis: norfloxacin 400 mg/day (long-term, after first SBP episode or if ascitic protein <1.5 g/dL + renal/hepatic impairment)

Hepatorenal Syndrome (HRS)

• Vasoconstrictors: terlipressin (first-line) or noradrenaline + albumin infusion
• TIPS as bridge to transplant
• Definitive treatment: liver transplantation

Hepatic Encephalopathy

• Lactulose (reduce ammonia via acidification of gut): first-line, titrate to 2-3 soft stools/day
• Rifaximin (non-absorbable antibiotic): added for recurrent/refractory encephalopathy or as secondary prophylaxis
• Identify and treat precipitating causes: infection, GI bleeding, electrolyte disturbances, constipation, medications

Hepatocellular Carcinoma (HCC) Surveillance

• All cirrhotic patients (Child-Pugh A or B) should undergo ultrasound ± AFP every 6 months
• Screening not indicated for Child-Pugh C (unless listed for transplant) or those with <12-month life expectancy

D. Liver Transplantation

• Only definitive cure for end-stage liver disease
• Indications: MELD score ≥15, refractory complications (HRS type 1, refractory ascites, recurrent SBP, hepatopulmonary syndrome), HCC within Milan criteria
• Contraindications: active alcoholism/drug use (typically 6-month abstinence required), extrahepatic malignancy, severe cardiopulmonary disease
• Post-transplant: immunosuppression (tacrolimus-based regimens), HCC surveillance
• Goldman-Cecil Medicine, p. 1618-1625

7. Recent Evidence Updates (2024-2026)

• Noninvasive liver staging (PMID: 38489521): A 2025 AASLD-supporting systematic review confirmed that imaging-based tools (transient elastography, MR elastography) are now validated for staging liver fibrosis, reducing the need for liver biopsy.
• GLP-1 receptor agonists for MASH/fibrosis (PMID: 40736113): A 2025 meta-analysis of RCTs found that GLP-1 agonists (semaglutide, liraglutide) significantly improve MASH resolution and liver fibrosis - an important emerging treatment option.
• Pharmacological therapy for MASH (PMID: 39903735): A 2025 network meta-analysis compared multiple agents for fibrosis regression and MASH resolution, helping guide treatment selection.
• Chinese 2025 cirrhosis guidelines introduced the concept of "recompensated cirrhosis" as a third clinical category and reinforced the EASL 6-stage classification system.

Summary Table

Clinical note: Regression of established cirrhosis is possible with effective treatment of the underlying cause (e.g., HCV cure, alcohol abstinence). Even patients with documented cirrhosis may achieve functional recovery with adequate etiology-directed therapy.

• Goldman-Cecil Medicine International Edition, pp. 1614-1625
• Robbins & Kumar Basic Pathology, pp. 597-601
• Chinese Guidelines for Clinical Diagnosis, Treatment, and Management of Cirrhosis (2025)
• AASLD Systematic Review on Noninvasive Liver Staging, Hepatology 2025 [PMID: 38489521]
• GLP-1 RA Meta-Analysis, Liver Int 2025 [PMID: 40736113]